MASV Drives Enterprise Media Workflow Transformation with Frame.io V4 Integration
OTTAWA, ON / ACCESS Newswire / April 3, 2025 / MASV, the fastest large file transfer platform for media professionals, is revolutionizing enterprise media workflows by enabling faster, more reliable, and scalable capture-to-cloud workflows through its upcoming integration with Frame.io V4.
This collaboration empowers media organizations, including sports and news enterprises, to streamline operations, automate manual tasks, and scale effortlessly to meet growing audience demands. By enabling faster, more reliable capture-to-cloud workflows, MASV helps businesses maximize operational efficiency and achieve seamless global collaboration in an increasingly fast-paced industry.
MASV transforms media workflows by automating the transfer and organization of massive files. It enables teams to deliver content to multiple destinations-such as Frame.io for review, on-prem storage for editing, and cloud backups for archiving-all in a single step. This means that for live sports broadcasts, reporters can upload game footage directly from the field, while news teams covering breaking stories can instantly transfer clips to editors and archives from remote assignments without delays. This streamlined process eliminates repetitive uploads, ensures immediate access to content, and scales effortlessly to handle the intense demands of real-time production environments.
"Shifting from linear 'chain of event' workflows to automated 'one-to-many' workflows enables us to break down the barriers of sequential file handling and enable rapidly scalable capture-to-cloud workflows that pave the way for seamless collaboration and unparalleled efficiency," says MASV CTO and Interim CEO, Majed Alhajry. "By eliminating delays and enabling real-time collaboration, we're fostering a more agile, future-ready infrastructure-aligned with the forward-thinking principles of the MovieLabs 2030 Vision."
Compliant with ISO27001, SOC 2, and a Gold member of the TPN vendor roster, MASV ensures enterprise-grade security for even the most sensitive projects. With robust encryption, secure access controls, and compliance with industry-leading security frameworks, MASV provides peace of mind for organizations managing critical workflows in an increasingly complex digital landscape.
"Seamless collaboration and efficient workflows are at the heart of what Frame.io provides, and this integration with MASV takes that to the next level," says Charlie Anderson, Head of Frame.io Partnerships at Adobe. "For businesses whose reputations depend on effectively managing large-scale projects, having a path to near-instant operational efficiency is invaluable. MASV brings a level of expertise and flexibility that complements our vision, offering tools that naturally fit into the fast-paced, cloud-driven workflows users can rely on."
For more information, please visit the MASV website.
Integration Availability
The MASV-Frame.io V4 integration will be available to all MASV users later in 2025.
See the MASV-Frame.io V4 Integration at the 2025 NAB Show
Learn how MASV's innovative "one-to-many" workflows are designed to increase efficiency and keep pace with the demands of today's fast-moving media and entertainment industry.
Book a one-on-one demonstration here.
About MASV
MASV is a cloud-based large file transfer platform designed to orchestrate file movement worldwide to meet fast-paced and nimble workflows. Global media organizations rely on MASV to automatically deliver their assets without any restrictions, allowing them to concentrate on their next big deliverable. To learn more and try MASV for free, visit massive.io.
Press Contact:
Melissa HardingGrithaus Agencymelissa@grithaus.agency+44 7594079738
SOURCE: MASV
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
a day ago
- Associated Press
OneMain Financial: What to Know Before Taking Out a Rent Loan
NEW YORK CITY, NY / ACCESS Newswire / August 9, 2025 / When money is tight, and rent is due, some people may look for quick solutions to stay in their homes. Rent loans are one option that could help in tough times. A rent loan provides a borrower with a lump sum of money to cover rent when they don't have enough money saved up. While rent loans might offer quick help, it's important to understand how they work and what to expect before applying. Understand the ins and outs of a rent loan A rent loan is a type of personal loan that helps a renter pay their housing costs if they don't have enough money in the bank. First, the consumer borrows a predetermined amount of money and will then typically pay it back over a set period of time by making fixed monthly payments. Each payment covers two parts of the loan. First is the loan principal, which is the original amount that's borrowed, and second is interest, which is the cost of borrowing. Qualified borrowers can apply for rent loans through different types of lenders, including online lenders, banks or credit unions. To get approved, the borrower typically needs a steady income and a favorable credit score - though eligibility requirements vary by lender. Consider a rent loan a quick fix, not a long-term solution A rent loan may help someone when money is tight, but it's not meant to solve long-term financial problems. A rent loan is a temporary solution that should only be used when there's a clear plan to repay it. For example, if someone is between jobs and has new employment starting soon, a rent loan might help bridge the gap. Similarly, if they're waiting on a delayed paycheck or emergency funds, the loan could help them stay on track. But if they don't know when they'll have a steady income again, taking out a loan could cause more harm than good. If a renter ends up needing to take out a rent loan every month just to stay afloat, it may be time to look for other types of help. Different types of financial support could include government assistance or even working out a payment plan with their landlord. Be mindful of any additional fees attached to the loan When taking out a rent loan, the interest rate isn't the only cost. There might be extra fees that result in making the loan more expensive. These might include: All these charges can increase the total cost of the loan. That's why it's important to ask questions and consider all the financial obligations before signing any loan agreement documents. Budgeting for monthly repayments is key It's important for someone to make sure they can repay a rent loan with interest in the given repayment period before they sign on the dotted line. Taking the time to calculate all monthly bills, including groceries, utilities, commuting costs and other regular expenses, and figuring out how a loan repayment fits in, could go a long way to helping someone avoid coming up short and worrying they will never catch up. Making monthly rent loan payments on time and in full may protect the borrower's credit score - but only as long as their other bills stay current too, because late or missed payments could damage the credit score. While a rent loan can help lower financial stress in the short term, it's important to make sure taking on debt doesn't add stress in the long term. Extra debt can be hard to manage without a clear plan for how it fits into someone's overall budget. A renter should make the best choice for their situation Rent loans can help in a tight spot, but they come with real costs. Before taking out a loan, it's important to look at the full picture - how much it will cost, how it will be repaid, how long it will take to be repaid, and whether other options are available. With careful planning and smart choices, it may be possible to stay on top of rent without falling deeper into debt. About OneMain Financial View Website OneMain Financial is the leader in offering nonprime customers responsible access to credit and is dedicated to improving the financial well-being of hardworking Americans. CONTACT: Sonakshi Murze Manager [email protected] SOURCE: OneMain Financial press release
Indianapolis Star
3 days ago
- Indianapolis Star
Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides
SHELTON, CT / ACCESS Newswire NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the 'Company'), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced that its drug candidate NV-387 is the weapon necessary for combatting growing cases of measles worldwide, especially in the industrialized world including, USA, Canada, UK, and European Union. NV-387 is possibly the only drug candidate that has been shown to be effective and safe in animal model studies of Measles virus in humanized h-CD150+ knock-in mice, as reported previously by NanoViricides. NV-387 has completed a Phase I clinical trial with no reported adverse events, indicating excellent safety and tolerability in humans. The development of NV-387 as a treatment for Measles can be accelerated under the US FDA programs. Measles is considered a rare orphan disease in the USA. As such, NV-387 for the treatment of Measles would qualify for an Orphan Drug Designation. Orphan drug designation qualifies sponsors for incentives including tax credits for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after approval [1]. The Company also plans to explore a 'Fast Track' designation for the NV-387 Measles indication. If granted, a drug approval can occur on the basis of a successful Phase II clinical trial without requiring a Phase III clinical trial, which significantly reduces the timeline to approval. Measles has become an important disease of concern globally in the recent years for several reasons. Most importantly, Measles disease can wipe out the previously learned immunity of the patient against many infections, including from prior infections, and non-live virus vaccines, making the population vulnerable to viruses that were encountered previously. This is because Measles virus attacks the CD150-bearing immune cells that are responsible for memorizing the prior infections and mounting defenses against them later. Measles is possibly the most communicable diseases, spreading through aerosol, that is known to humans. In patients, it produces severe morbidity with skin rash, pain, fatigue, and other syndromes. Rarely it can cause a brain disease. Measles mostly affects children. There were a total of 1,319 confirmed measles cases reported in the USA as of July 22, breaking the most recent record of 1,274 cases in 2019. Hospitalization rates for measles in the USA are about 13%, and fatalities are rare, although in 2025 there were three deaths to date. Canada is having a much worse Measles season than the USA, with more than 3,800 cases [2] to date in 2025. A Measles holiday warning has been issued in the UK this year [3]. England itself had more than 3,000 cases of Measles in 2024. In the European Region, 127,350 measles cases were reported for 2024, double the number of cases reported for 2023 and the highest number since 1997, according to an analysis by WHO and the United Nations Children's Fund (UNICEF) [4]. Worldwide, Measles cases continue to occur every year. Globally, there have been about 108,000 confirmed measles cases in 2025 to date, while in 2024 there were about 360,000 confirmed cases, according to the WHO [5]. A sustained measles vaccination rate of at least 95% is estimated to be required to maintain community immunity ('herd immunity'). Such a high rate is becoming increasingly difficult to achieve even in developed countries where access to vaccination is not an issue. While growing vaccine hesitancy is considered an important reason for the fall in Measles vaccination rates, two other factors are of importance as well: (i) The overall population in the industrialized world, as well as in developing world, has increased frequency of immune dysfunction, obesity, and diabetes. The people with immune dysfunction or immune compromise are less likely to benefit from almost any standard vaccination as compared to healthy people and are likely to result in breakthrough infections. (ii) Additionally, the current vaccine for Measles is a live attenuated vaccine of the 1968 era, and the virus has evolved well past that, although so far the Measles virus strains continue to be susceptible to antibodies produced from the standard vaccine; this can change with continuing circulation of the virus in vaccinated persons and can result in a virus that can substantially defeat the vaccine [6]. Further, vaccine hesitancy itself is not irrational because the standard Measles vaccine is a live attenuated vaccine to be given to infants at early age; it is a virus infection that continues to remain in the subject, which is why it provides lifelong immunity. Measles infection itself also provides lifelong immunity that includes the current strains of the virus. Thus, the Company projects continuing Measles cases worldwide, that require a drug to control the disease in the patient and its spread to others. We believe NV-387 fills this important medical need. There is no approved drug for treatment of Measles at present. ABOUT NANOVIRICIDES NanoViricides, Inc. (the 'Company') ( is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development. Public Relations Contact: ir@ View the original press release on ACCESS Newswire The post Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides appeared first on DA80 Hub.
Business Wire
3 days ago
- Business Wire
ERI's John Shegerian Describes the Evolving Circular Economy at 2025 ITAD Summit
LAS VEGAS--(BUSINESS WIRE)--John Shegerian, Chairman and CEO of ERI, the nation's first carbon neutral resource recovery, ITAD, mobility and data destruction/processing provider, participated in the Day 2 opening panel conversation on the circular economy last week at the ITAD Summit at the Bellagio Hotel & Casino in Las Vegas. The discussion was emceed by Darrell Fleming-Kendall, the Events Manager and Special Projects Director for the ITAD Summit, and the panel featured experts Shegerian from ERI; Jennifer Foxworthy from HP; and Miranda Clark from TEMU. Shegerian and the panel engaged in a discussion titled 'ITAD and the Circular Economy from Multiple Perspectives.' The panel covered the role of the circular economy in ITAD today and in the future. The panel also engaged in a spirited Q&A discussion with the audience. 'We had our biggest turnout yet for the ITAD Summit this year,' said Robert Tokarchyk, CEO of RazorERP, producers of the event. 'At the ITAD Summit events we aim to spark proactive conversation and discussion of best practices across the rapidly evolving ITAD landscape. It has been rewarding to be able to provide an event where our attendees can engage with the very best of the industry's thought-leaders, suppliers and pioneers, like John Shegerian.' 'We're grateful to have been asked by the ITAD Summit to participate in these spirited discussions about the role the circular economy plays in the IT asset disposition field at such an important conference,' said Shegerian. "It's essential that we as an industry focus on the various ways we can innovate sustainably. And each step of the way, we must never lose sight of the importance of responsible recycling.' ITAD Summit is a collaborative forum covering advances in technology, IT processes, and trends that help organizations expand their possibilities. ERI is the first material resource recovery, ITAD and mobility recycling company that is carbon neutral and zero waste. ERI is certified at the highest level by all leading environmental and data security oversight organizations to de-manufacture, recycle, and refurbish every type of electronic device in an environmentally responsible manner. It is the first and only company in its industry to achieve carbon neutrality at all its facilities nationwide, and the first to achieve ISO 27001 and SOC 2 Type II certifications for security and data protection. ERI has the capacity to process more than a billion pounds of electronic waste annually at its eight certified locations, serving every zip code in the United States. ERI's mission is to protect people, the planet and privacy. For more information about ITAD services and e-waste recycling at ERI, call 1-800-ERI-DIRECT or visit
